CHEMICALS SUMMARY PAGE

Levetiracetam

Summary Information
Classification Chemicals / Complex Chemical Agents / Type:

(This chemicals section is currently predominantly used in Wildpro to link different data types and demonstrate inter-relationships. It does not contain detailed information on the chemical itself.)

Alternative Names --
Notes Information in this page has been entered to support the current volumes of Wildpro and further information will be added as new volumes are completed. This page is not intended to substitute for the manufacturer's data sheet and the information is not yet complete for all species, or for all contra-indications etc.

CAUTION: Before any pharmaceutical product is used, the manufacturer's data sheet, containing information on uses, dosage and administration, contra-indications, warnings etc., should always be consulted. It is important to remember that licensing of pharmaceutical products for use in a particular species/condition, as well as mandatory meat and milk withdrawal times for food-producing animals, varies between countries and changes with time. Withdrawal times also may vary between different pharmaceutical formulations and depending on route of administration. In the EU, the prescription cascade must be followed (see LCofC1.2H and W564.Apr05.w1); note that specific restrictions apply for food-producing animals. In the USA, FARAD may be consulted regarding residues and meat and milk withdrawal times.

  • In humans, licensed for use in treatment or adjunct therapy of partial (focal) seizures with or without secondary generalisation, also for adjunct therapy of myoclonic seizures. (B683.4.w4)
  • Caution in individuals with hepatic or renal impairment. (B683.4.w4)
  • Avoid sudden withdrawal. (B683.4.w4)
  • Numerous potential side effects. (B683.4.w4)
Administration
  • Human:
    • Adult/adolescent over 50 kg, initial dose 500 mg orally or by intravenous infusion, twice daily and adjusted in steps of 500 mg twice daily ecery 2-4 weeks, to a maximum of 1.5 g twice daily. (B683.4.w4)
    • Child/adolescent 4-18 years (or 12-18 years for myoclonic seizures), body weight under 50 kg, initial 10 mg/kg twice daily and adjusted in steps of not more than 10 mg.kg twice daily very two weeks to a maximum of 30 mg/kg twice daily. (B683.4.w4)
    • (Available as tablets, oral solution and concentrate for intravenous infusion). (B683.4.w4)

Great Apes

Return to Top of Page